Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction - PubMed (original) (raw)
Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction
Pss Rao et al. J Pers Nanomed. 2015.
Abstract
Chronic drug abuse is associated with elevated extracellular glutamate concentration in the brain reward regions. Deficit of glutamate clearance has been identified as a contributing factor that leads to enhanced glutamate concentration following extended drug abuse. Importantly, normalization of glutamate level through induction of glutamate transporter 1 (GLT1)/ excitatory amino acid transporter 2 (EAAT2) expression has been described in several in vivo studies. GLT1 upregulators including ceftriaxone, a beta-lactam antibiotic, have been effective in attenuating drug-seeking and drug-consumption behavior in rodent models. However, potential obstacles toward clinical translation of GLT1 (EAAT2) upregulators as treatment for drug addiction might include poor gastrointestinal absorption, serious peripheral adverse effects, and/or suboptimal CNS concentrations. Given the growing success of nanotechnology in targeting CNS ailments, nanoformulating known GLT1 (EAAT2) upregulators for selective uptake across the blood brain barrier presents an ideal therapeutic approach for treating drug addiction. In this review, we summarize the results obtained with promising GLT1 (EAAT2) inducing compounds in animal models recapitulating drug addiction. Additionally, the various nanoformulations that can be employed for selectively increasing the CNS bioavailability of GLT1 (EAAT2) upregulators are discussed. Finally, the applicability of GLT1 (EAAT2) induction via central delivery of drug-loaded nanoformulations is described.
Keywords: Drug addiction; EAAT2; Glutamate; Nanoparticles; Transcytosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Figure 1
A schematic diagram of proposed mechanism of action for ceftriaxone-loaded nanoparticles. Antibody targeting the transferrin receptors will facilitate the selective uptake of ceftriaxone-loaded nanoparticles across the blood brain barrier. Upon entering the brain, the ceftriaxone released from these nanoparticles will induce the expression of GLT1 (EAAT2) in glial cell. Increased levels of glutamate transporters will facilitate the reuptake of glutamate and decrease the extracellular glutamate concentrations. The resumption of glutamate homeostasis will in principle result in attenuation of drug-seeking behavior.
Similar articles
- Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, Serena J, Vivancos J, Nombela F, Lorenzo P, Lizasoain I, Moro MA. Romera C, et al. J Cereb Blood Flow Metab. 2007 Jul;27(7):1327-38. doi: 10.1038/sj.jcbfm.9600438. Epub 2007 Jan 10. J Cereb Blood Flow Metab. 2007. PMID: 17213861 - Effects of ceftriaxone on GLT1 isoforms, xCT and associated signaling pathways in P rats exposed to ethanol.
Rao PS, Saternos H, Goodwani S, Sari Y. Rao PS, et al. Psychopharmacology (Berl). 2015 Jul;232(13):2333-42. doi: 10.1007/s00213-015-3868-3. Epub 2015 Jan 27. Psychopharmacology (Berl). 2015. PMID: 25619881 Free PMC article. - Potential therapeutic role of glutamate transporter 1 for the treatment of alcohol dependence.
Sari Y. Sari Y. OA Alcohol. 2013;1(1):6. doi: 10.13172/2053-0285-1-1-574. OA Alcohol. 2013. PMID: 24409344 Free PMC article. - GLAST But Not Least--Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain--Focus on GLAST/EAAT1.
Šerý O, Sultana N, Kashem MA, Pow DV, Balcar VJ. Šerý O, et al. Neurochem Res. 2015 Dec;40(12):2461-72. doi: 10.1007/s11064-015-1605-2. Epub 2015 May 14. Neurochem Res. 2015. PMID: 25972039 Review. - Current approaches to enhance glutamate transporter function and expression.
Fontana AC. Fontana AC. J Neurochem. 2015 Sep;134(6):982-1007. doi: 10.1111/jnc.13200. Epub 2015 Aug 14. J Neurochem. 2015. PMID: 26096891 Review.
Cited by
- Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective.
Yang XM, Yu H, Li JX, Li N, Li C, Xu DH, Zhang H, Fang TH, Wang SJ, Yan PY, Han BB. Yang XM, et al. Mol Neurobiol. 2024 Apr 25. doi: 10.1007/s12035-024-04184-7. Online ahead of print. Mol Neurobiol. 2024. PMID: 38662299 Review. - Histone 3 Trimethylation Patterns are Associated with Resilience or Stress Susceptibility in a Rat Model of Major Depression Disorder.
Santos L, Behrens L, Barbosa C, Tiefensee-Ribeiro C, Rosa-Silva H, Somensi N, Brum PO, Silveira AK, Rodrigues MS, de Oliveira J, Gelain DP, Almeida RF, Moreira JCF. Santos L, et al. Mol Neurobiol. 2024 Aug;61(8):5718-5737. doi: 10.1007/s12035-024-03912-3. Epub 2024 Jan 16. Mol Neurobiol. 2024. PMID: 38225513 - Immunological Markers for Central Nervous System Glia.
Huang H, He W, Tang T, Qiu M. Huang H, et al. Neurosci Bull. 2023 Mar;39(3):379-392. doi: 10.1007/s12264-022-00938-2. Epub 2022 Aug 26. Neurosci Bull. 2023. PMID: 36028641 Free PMC article. Review. - The Role of SLC7A11 in Cancer: Friend or Foe?
Li S, Lu Z, Sun R, Guo S, Gao F, Cao B, Aa J. Li S, et al. Cancers (Basel). 2022 Jun 22;14(13):3059. doi: 10.3390/cancers14133059. Cancers (Basel). 2022. PMID: 35804831 Free PMC article. Review. - nMOWChIP-seq: low-input genome-wide mapping of non-histone targets.
Liu Z, Naler LB, Zhu Y, Deng C, Zhang Q, Zhu B, Zhou Z, Sarma M, Murray A, Xie H, Lu C. Liu Z, et al. NAR Genom Bioinform. 2022 Apr 7;4(2):lqac030. doi: 10.1093/nargab/lqac030. eCollection 2022 Jun. NAR Genom Bioinform. 2022. PMID: 35402909 Free PMC article.
References
- SAMHSA. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services; 2011.
LinkOut - more resources
Full Text Sources
Other Literature Sources